Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » Administration of broadly neutralizing anti-HIV-1 antibod...

Om AU

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Standard

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. / Rosás-Umbert, Miriam; Gunst, Jesper D.; Pahus, Marie H. et al.
I: Nature Communications, Bind 13, 6473, 10.2022.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Harvard

Rosás-Umbert, M, Gunst, JD, Pahus, MH, Olesen, R, Schleimann, M, Denton, PW, Ramos, V, Ward, A, Kinloch, NN, Copertino, DC, Escribà, T, Llano, A, Brumme, ZL, Brad Jones, R, Mothe, B, Brander, C, Fox, J, Nussenzweig, MC, Fidler, S, Caskey, M, Tolstrup, M & Søgaard, OS 2022, 'Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity', Nature Communications, bind 13, 6473. https://doi.org/10.1038/s41467-022-34171-2

APA

Rosás-Umbert, M., Gunst, J. D., Pahus, M. H., Olesen, R., Schleimann, M., Denton, P. W., Ramos, V., Ward, A., Kinloch, N. N., Copertino, D. C., Escribà, T., Llano, A., Brumme, Z. L., Brad Jones, R., Mothe, B., Brander, C., Fox, J., Nussenzweig, M. C., Fidler, S., ... Søgaard, O. S. (2022). Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. Nature Communications, 13, artikel 6473. https://doi.org/10.1038/s41467-022-34171-2

CBE

Rosás-Umbert M, Gunst JD, Pahus MH, Olesen R, Schleimann M, Denton PW, Ramos V, Ward A, Kinloch NN, Copertino DC, et al. 2022. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. Nature Communications. 13:Article 6473. https://doi.org/10.1038/s41467-022-34171-2

MLA

Rosás-Umbert, Miriam et al. "Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity". Nature Communications. 2022. 13. https://doi.org/10.1038/s41467-022-34171-2

Vancouver

Rosás-Umbert M, Gunst JD, Pahus MH, Olesen R, Schleimann M, Denton PW et al. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. Nature Communications. 2022 okt.;13:6473. doi: 10.1038/s41467-022-34171-2

Author

Rosás-Umbert, Miriam ; Gunst, Jesper D. ; Pahus, Marie H. et al. / Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. I: Nature Communications. 2022 ; Bind 13.

Bibtex

@article{cb5326f6ac234d4bbc5d5b9bb7495fbf,
title = "Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity",
abstract = "In simian-human immunodeficiency virus (SHIV)-infected non-human primates, broadly neutralizing antibodies (bNAbs) against the virus appear to stimulate T cell immunity. To determine whether this phenomenon also occurs in humans we measured HIV-1-specific cellular immunity longitudinally in individuals with HIV-1 starting antiviral therapy (ART) with or without adjunctive bNAb 3BNC117 treatment. Using the activation-induced marker (AIM) assay and interferon-γ release, we observe that frequencies of Pol- and Gag-specific CD8+ T cells, as well as Gag-induced interferon-γ responses, are significantly higher among individuals that received adjunctive 3BNC117 compared to ART-alone at 3 and 12 months after starting ART. The observed changes in cellular immunity were directly correlated to pre-treatment 3BNC117-sensitivity. Notably, increased HIV-1-specific immunity is associated with partial or complete ART-free virologic control during treatment interruption for up to 4 years. Our findings suggest that bNAb treatment at the time of ART initiation maintains HIV-1-specific CD8+ T cell responses that are associated with ART-free virologic control.",
author = "Miriam Ros{\'a}s-Umbert and Gunst, {Jesper D.} and Pahus, {Marie H.} and Rikke Olesen and Mariane Schleimann and Denton, {Paul W.} and Victor Ramos and Adam Ward and Kinloch, {Natalie N.} and Copertino, {Dennis C.} and Tuixent Escrib{\`a} and Anuska Llano and Brumme, {Zabrina L.} and {Brad Jones}, R. and Beatriz Mothe and Christian Brander and Julie Fox and Nussenzweig, {Michel C.} and Sarah Fidler and Marina Caskey and Martin Tolstrup and S{\o}gaard, {Ole S.}",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = oct,
doi = "10.1038/s41467-022-34171-2",
language = "English",
volume = "13",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity

AU - Rosás-Umbert, Miriam

AU - Gunst, Jesper D.

AU - Pahus, Marie H.

AU - Olesen, Rikke

AU - Schleimann, Mariane

AU - Denton, Paul W.

AU - Ramos, Victor

AU - Ward, Adam

AU - Kinloch, Natalie N.

AU - Copertino, Dennis C.

AU - Escribà, Tuixent

AU - Llano, Anuska

AU - Brumme, Zabrina L.

AU - Brad Jones, R.

AU - Mothe, Beatriz

AU - Brander, Christian

AU - Fox, Julie

AU - Nussenzweig, Michel C.

AU - Fidler, Sarah

AU - Caskey, Marina

AU - Tolstrup, Martin

AU - Søgaard, Ole S.

N1 - Publisher Copyright: © 2022, The Author(s).

PY - 2022/10

Y1 - 2022/10

N2 - In simian-human immunodeficiency virus (SHIV)-infected non-human primates, broadly neutralizing antibodies (bNAbs) against the virus appear to stimulate T cell immunity. To determine whether this phenomenon also occurs in humans we measured HIV-1-specific cellular immunity longitudinally in individuals with HIV-1 starting antiviral therapy (ART) with or without adjunctive bNAb 3BNC117 treatment. Using the activation-induced marker (AIM) assay and interferon-γ release, we observe that frequencies of Pol- and Gag-specific CD8+ T cells, as well as Gag-induced interferon-γ responses, are significantly higher among individuals that received adjunctive 3BNC117 compared to ART-alone at 3 and 12 months after starting ART. The observed changes in cellular immunity were directly correlated to pre-treatment 3BNC117-sensitivity. Notably, increased HIV-1-specific immunity is associated with partial or complete ART-free virologic control during treatment interruption for up to 4 years. Our findings suggest that bNAb treatment at the time of ART initiation maintains HIV-1-specific CD8+ T cell responses that are associated with ART-free virologic control.

AB - In simian-human immunodeficiency virus (SHIV)-infected non-human primates, broadly neutralizing antibodies (bNAbs) against the virus appear to stimulate T cell immunity. To determine whether this phenomenon also occurs in humans we measured HIV-1-specific cellular immunity longitudinally in individuals with HIV-1 starting antiviral therapy (ART) with or without adjunctive bNAb 3BNC117 treatment. Using the activation-induced marker (AIM) assay and interferon-γ release, we observe that frequencies of Pol- and Gag-specific CD8+ T cells, as well as Gag-induced interferon-γ responses, are significantly higher among individuals that received adjunctive 3BNC117 compared to ART-alone at 3 and 12 months after starting ART. The observed changes in cellular immunity were directly correlated to pre-treatment 3BNC117-sensitivity. Notably, increased HIV-1-specific immunity is associated with partial or complete ART-free virologic control during treatment interruption for up to 4 years. Our findings suggest that bNAb treatment at the time of ART initiation maintains HIV-1-specific CD8+ T cell responses that are associated with ART-free virologic control.

UR - http://www.scopus.com/inward/record.url?scp=85140927548&partnerID=8YFLogxK

U2 - 10.1038/s41467-022-34171-2

DO - 10.1038/s41467-022-34171-2

M3 - Journal article

C2 - 36309514

AN - SCOPUS:85140927548

VL - 13

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 6473

ER -